Clinical Trial Detail

NCT ID NCT03990961
Title Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.